You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 22, 2024

~ Buy the TUXARIN ER (chlorpheniramine maleate; codeine phosphate) Drug Profile, 2024 PDF Report in the Report Store ~

TUXARIN ER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tuxarin Er patents expire, and what generic alternatives are available?

Tuxarin Er is a drug marketed by Mainpointe and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in TUXARIN ER is chlorpheniramine maleate; codeine phosphate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chlorpheniramine maleate; codeine phosphate profile page.

DrugPatentWatch® Generic Entry Outlook for Tuxarin Er

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 3, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for TUXARIN ER
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TUXARIN ER
Generic Entry Date for TUXARIN ER*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TUXARIN ER

TUXARIN ER is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TUXARIN ER is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TUXARIN ER

Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS

Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 RX No No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TUXARIN ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 ⤷  Try a Trial ⤷  Try a Trial
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TUXARIN ER

See the table below for patents covering TUXARIN ER around the world.

Country Patent Number Title Estimated Expiration
Japan 2003503440 ⤷  Try a Trial
Canada 2366702 COMPOSITIONS ET PROCEDES D'ADMINISTRATION AMELIOREE D'AGENTSTHERAPEUTIQUES HYDROPHOBES IONISABLES (COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS) ⤷  Try a Trial
Japan 2011201914 CLEAR OIL-CONTAINING PHARMACEUTICAL COMPOSITION ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.